{"id":"almonertinib-plus-carboplatin-and-pemetrexed","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Almonertinib is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to mutant EGFR, particularly effective against common mutations and some resistant variants. Carboplatin is a platinum agent that causes DNA crosslinking and cell death, while pemetrexed is an antifolate that inhibits multiple enzymes in nucleotide synthesis. The combination leverages targeted therapy with almonertinib alongside conventional chemotherapy for enhanced efficacy.","oneSentence":"Almonertinib inhibits EGFR tyrosine kinase while carboplatin and pemetrexed provide platinum-based chemotherapy and antimetabolite activity, respectively, to target non-small cell lung cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:58.365Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic non-small cell lung cancer with EGFR mutations"}]},"trialDetails":[{"nctId":"NCT04923906","phase":"PHASE3","title":"Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2021-08-11","conditions":"Non-small Cell Lung Cancer","enrollment":624},{"nctId":"NCT06474455","phase":"PHASE1, PHASE2","title":"A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-06","conditions":"Advanced Solid Tumors","enrollment":156},{"nctId":"NCT05493501","phase":"PHASE3","title":"Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"EQRx International, Inc.","startDate":"2022-12-14","conditions":"NSCLC","enrollment":8},{"nctId":"NCT06110663","phase":"PHASE3","title":"A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2023-12-30","conditions":"Non-Small Cell Lung Cancer","enrollment":314},{"nctId":"NCT04951648","phase":"PHASE3","title":"A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2021-07-15","conditions":"Non-small Cell Lung Cancer","enrollment":220},{"nctId":"NCT04646824","phase":"PHASE2","title":"Almonertinib With Chemotherapy in mEGFR NSCLC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2020-11-19","conditions":"Non-Small Cell Lung Cancer Metastatic","enrollment":10},{"nctId":"NCT04592666","phase":"PHASE2","title":"Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-10-09","conditions":"Lung Cancer, Non-small Cell, EGFR T790M, EGFR Gene Mutation","enrollment":226},{"nctId":"NCT04500717","phase":"PHASE3","title":"Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-10","conditions":"Non Small Cell Lung Cancer","enrollment":460},{"nctId":"NCT04500704","phase":"PHASE3","title":"Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-10","conditions":"Non Small Cell Lung Cancer","enrollment":166},{"nctId":"NCT04455594","phase":"PHASE2","title":"Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2020-10","conditions":"Non-Small Cell Lung Cancer Stage IIIA","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aleime","Ameile"],"phase":"phase_3","status":"active","brandName":"Almonertinib plus carboplatin and pemetrexed","genericName":"Almonertinib plus carboplatin and pemetrexed","companyName":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","companyId":"cancer-institute-and-hospital-chinese-academy-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Almonertinib inhibits EGFR tyrosine kinase while carboplatin and pemetrexed provide platinum-based chemotherapy and antimetabolite activity, respectively, to target non-small cell lung cancer. Used for Advanced or metastatic non-small cell lung cancer with EGFR mutations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}